Clinical trial
17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic…
NCT00119236 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00119236 |
|---|---|
| Title | 17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors |
| Official title | An Open-Labeled Non-Randomized Phase I Study of 17-N-allylamino-17-demethoxy Geldanamycin (17AAG) Administered With Irinotecan (CPT-11) in Patients With Advanced Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | tanespimycin, irinotecan hydrochloride |
| Enrollment | 48 |
| Start date | May 1, 2005 |
| Primary completion | Oct 1, 2008 |
| First posted | Jul 13, 2005 |
| Last update posted | Jun 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: